The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center
Abstract Background Myelodysplastic syndrome (MDS) is a rare disease in children and the treatment option before the allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rarely reported. Our main objective was to report our single-center experience with the DNA-hypomethylating agent, de...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMC
2022-05-01
|
| Серии: | BMC Pediatrics |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1186/s12887-022-03376-1 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|